Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

Resources, Guidance, & Updates


COVID-19 regulatory guidance

Celerion COVID Entry Requirements

FDA


FDA guidance on conduct of clinical trials

Read More

FDA


Developing drugs & biological products for treatment

Learn More

FDA


Development and licensure of vaccines to prevent COVID-19

Read More

EMA


Implications on methodological aspects of ongoing clinical trials

Read More

EMA


Guidance for medicine developers and companies on COVID-19

Read More

MHRA


Guidance on coronavirus (COVID-19)

Read More

Contact

Get Your Drug to Market Faster.

Work with a CRO that generates fast, actionable data you can rely on.

Contact Us